Biomea Fusion is a biopharmaceutical company focused on the discovery and development of irreversible covalent small molecules to treat patients with genetically defined cancers and metabolic diseases. Utilizing its knowledge in irreversible binding chemistry and development, Co. built its proprietary FUSION System discovery platform to advance a pipeline of irreversible covalent small molecule product candidates. Co.'s product candidate, BMF-219, is designed to be an orally bioavailable, potent and selective irreversible covalent inhibitor of menin, a transcriptional regulator known to play a direct role in oncogenic signaling in multiple cancers. The BMEA stock yearly return is shown above.
The yearly return on the BMEA stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2022 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the BMEA annual return calculation with any dividends reinvested as applicable (on ex-dates).
|